source
- Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trialData presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…
- Revolution Medicines' pancreatic cancer trial shows striking positive resultsAt the American Society of Clinical Oncology meeting, Revolution Medicines presented data from its pivotal pancreatic cancer trial that impressed many observers. Oncologist Brian Wolpin described…